Adamas Pharmaceuticals (ADMS) Stock Price, News & Analysis

Company Overview

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Key Stats

• Today's Range: $8.22 to $8.22
• 50-Day Range: $7.97 to $8.23
• 52-Week Range: $4.02 to $9.15
• Volume: N/A
• Average Volume: 692,487 shs
• Market Capitalization: $376.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ADMS Stock Analysis - Frequently Asked Questions

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) released its earnings results on Thursday, November, 11th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.21. The specialty pharmaceutical company had revenue of $25.90 million for the quarter, compared to analysts' expectations of $25.07 million.

What other stocks do shareholders of Adamas Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adamas Pharmaceuticals investors own include Rite Aid (RAD), VBI Vaccines (VBIV), Amarin (AMRN), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Exelixis (EXEL).

Company Calendar

• Last Earnings: 11/11/2021
• Today: 4/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ADMS
• CIK: 1328143
• Web: www.adamaspharma.com
• Phone: (510) 450-3500
• Fax: 510-428-0519
• Employees: 138
• Year Founded: 2002

Profitability

• EPS (Most Recent Fiscal Year): ($1.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-57,400,000.00
• Net Margins: -71.11%
• Pretax Margin: -71.11%
• Return on Equity: N/A
• Return on Assets: -42.96%

Debt

• Debt-to-Equity Ratio: 21.25
• Current Ratio: 4.53
• Quick Ratio: 4.17

Sales & Book Value

• Annual Sales: $74.46 million
• Price / Sales: 5.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.47) per share
• Price / Book: -17.49

Miscellaneous

• Outstanding Shares: 45,787,000
• Free Float: 37,133,000
• Market Cap: $376.37 million
• Optionable: Optionable
• Beta: 2.82